Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PAPRAT

Financiado

Cerrado

PAPRAT Predictive Algorithm for Pre Rheumatoid Arthritis Treatment . The new a...

PAPRAT Predictive Algorithm for Pre Rheumatoid Arthritis Treatment . The new and most efficient multiple biomarkers based system for an early selection of RA treatment intensity Rheumatoid arthritis (RA) affects 1% of world population (17.6 M) and it is a relevant economic burden (€45 Bn spent yearly in Europe). It is a degenerative disease that affects bone health, cause joints’ deformity, impact other o... ver más

29/02/2020

MAKING GENETICS

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

MAKING GENETICS Constituye el objeto social: a.- la prestación de servicios de medicina personalizada. b.- la identificación y comercialización de nuevos bi...

TRL 4-5 | 50K€

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-02-29

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

MAKING GENETICS

50.00K€ | Lider

ENVASADOS DEL PIRINEO

271.71K€ | Participante

SOMVITAL

365.41K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EURO-TEAM Towards Early diagnosis and biomarker validation in Arthriti... 8M€ Cerrado

STRATA-FIT Stratification of Rheumatoid Arthritis: CompuTational models... 6M€ Cerrado

RTC-2015-3562-1 Desarrollo y Validación clínica de un sistema de análisis de... 49K€ Cerrado

RABIOPRED RABIOPRED Clinical validation of BIOmarker assay to PREDic... 5M€ Cerrado

DESARROLLO DE NUEVOS MÉTODOS GENÓMICOS Y PROT... DESARROLLO DE NUEVOS MÉTODOS GENÓMICOS Y PROTEÓMICOS PARA EL... 292K€ Cerrado

Duración del proyecto: 6 meses Fecha Inicio: 2019-08-02
Fecha Fin: 2020-02-29

Líder del proyecto

MAKING GENETICS Constituye el objeto social: a.- la prestación de servicios de medicina personalizada. b.- la identificación y comercialización de nuevos bi...

TRL 4-5 | 50K€

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Rheumatoid arthritis (RA) affects 1% of world population (17.6 M) and it is a relevant economic burden (€45 Bn spent yearly in Europe). It is a degenerative disease that affects bone health, cause joints’ deformity, impact other organs and cause disability. An early and personalized treatment can greatly improve its outcome, achieve remission and reduce pain, thus an accurate prognosis is critical for its efficient management. However, this is difficult for the lack of good prognosis factors (currently rheumatoid factor-RF or anti-citrullinated protein antibodies-ACPA), which at present are very few, poorly accurate and leave 40% of patients unclassified (suffering health complications due to an unnecessary aggressive treatment or from deterioration due to delays in proper treatment). Making Genetics is a Spanish start-up focused in personalized medicine through genomic approaches. We have designed and developed a prognostics test for RA based on a blood test and the use of our new PAPRAT algorithm, with 82.4% accuracy. PAPRAT is a multiple biomarker-based system capable of classifying pre-rheumatoid arthritis patients, discerning which will need a more aggressive treatment. It combines unique genomic markers (genetic and epigenetic), as well as clinical and demographical variables, to calculate a predictive index and classify patients’ RA severity as HIGH (needing early administration of a combined therapy with biological DMARDs) or LOW and MEDIUM (non-biological DMARDs are enough). It is at a TRL6 and now we aim to optimize it, further validate it, develop a software platform and prepare its market launch. RA is expected to grow by drivers such as an ageing population or the continued uptake of biosimilars, and we have currently a total addressable market of 17.6 M patients globally and of around 3M in Europe. We will offer a complete prognosis service, including the blood testing, as well as the licensing of our software platform once it is finished.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores